Treatment of infarct related heart failure: Vasodilators other than ACE inhibitors

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Vasodilator drugs, particularly intravenously infused nitroprusside and an orally administered combination of hydralazine and isosorbide dinitrate, exert a profoundly favorable hemodynamic effect in the setting of heart failure complicating a prior myocardial infarction. Although these oral drugs also may relieve symptoms and improve exercise tolerance, the long-term benefits appear to be related to inhibition or reversal of the left ventricular dilation that results in a progressive fall in left ventricular ejection fraction. The long-term efficacy of both ACE inhibitors and hydralazine-nitrate in symptomatic heart failure makes the vasodilator combination a rational alternative to an ACE inhibitor and possibly an effective agent for cotherapy with an ACE inhibitor. Trials are needed to test the additive efficacy of this vasodilator combination and to develop other safe and effective drugs that target the progressive remodeling process in heart failure.

Original languageEnglish (US)
Pages (from-to)119-122
Number of pages4
JournalCardiovascular Drugs and Therapy
Volume8
Issue number1
DOIs
StatePublished - Feb 1 1994

Fingerprint

Vasodilator Agents
Angiotensin-Converting Enzyme Inhibitors
Heart Failure
Hydralazine
Exercise Tolerance
Nitroprusside
Pharmaceutical Preparations
Nitrates
Stroke Volume
Dilatation
Hemodynamics
Myocardial Infarction

Keywords

  • ejection fraction
  • exercise tolerance
  • hydralazine
  • isosorbide dinitrate
  • left ventricular remodeling

Cite this

Treatment of infarct related heart failure : Vasodilators other than ACE inhibitors. / Cohn, Jay N.

In: Cardiovascular Drugs and Therapy, Vol. 8, No. 1, 01.02.1994, p. 119-122.

Research output: Contribution to journalArticle

@article{f7d9843fe6f149bf9c1a1ffd964f4c74,
title = "Treatment of infarct related heart failure: Vasodilators other than ACE inhibitors",
abstract = "Vasodilator drugs, particularly intravenously infused nitroprusside and an orally administered combination of hydralazine and isosorbide dinitrate, exert a profoundly favorable hemodynamic effect in the setting of heart failure complicating a prior myocardial infarction. Although these oral drugs also may relieve symptoms and improve exercise tolerance, the long-term benefits appear to be related to inhibition or reversal of the left ventricular dilation that results in a progressive fall in left ventricular ejection fraction. The long-term efficacy of both ACE inhibitors and hydralazine-nitrate in symptomatic heart failure makes the vasodilator combination a rational alternative to an ACE inhibitor and possibly an effective agent for cotherapy with an ACE inhibitor. Trials are needed to test the additive efficacy of this vasodilator combination and to develop other safe and effective drugs that target the progressive remodeling process in heart failure.",
keywords = "ejection fraction, exercise tolerance, hydralazine, isosorbide dinitrate, left ventricular remodeling",
author = "Cohn, {Jay N}",
year = "1994",
month = "2",
day = "1",
doi = "10.1007/BF00877099",
language = "English (US)",
volume = "8",
pages = "119--122",
journal = "Cardiovascular Drugs and Therapy",
issn = "0920-3206",
publisher = "Kluwer Academic Publishers",
number = "1",

}

TY - JOUR

T1 - Treatment of infarct related heart failure

T2 - Vasodilators other than ACE inhibitors

AU - Cohn, Jay N

PY - 1994/2/1

Y1 - 1994/2/1

N2 - Vasodilator drugs, particularly intravenously infused nitroprusside and an orally administered combination of hydralazine and isosorbide dinitrate, exert a profoundly favorable hemodynamic effect in the setting of heart failure complicating a prior myocardial infarction. Although these oral drugs also may relieve symptoms and improve exercise tolerance, the long-term benefits appear to be related to inhibition or reversal of the left ventricular dilation that results in a progressive fall in left ventricular ejection fraction. The long-term efficacy of both ACE inhibitors and hydralazine-nitrate in symptomatic heart failure makes the vasodilator combination a rational alternative to an ACE inhibitor and possibly an effective agent for cotherapy with an ACE inhibitor. Trials are needed to test the additive efficacy of this vasodilator combination and to develop other safe and effective drugs that target the progressive remodeling process in heart failure.

AB - Vasodilator drugs, particularly intravenously infused nitroprusside and an orally administered combination of hydralazine and isosorbide dinitrate, exert a profoundly favorable hemodynamic effect in the setting of heart failure complicating a prior myocardial infarction. Although these oral drugs also may relieve symptoms and improve exercise tolerance, the long-term benefits appear to be related to inhibition or reversal of the left ventricular dilation that results in a progressive fall in left ventricular ejection fraction. The long-term efficacy of both ACE inhibitors and hydralazine-nitrate in symptomatic heart failure makes the vasodilator combination a rational alternative to an ACE inhibitor and possibly an effective agent for cotherapy with an ACE inhibitor. Trials are needed to test the additive efficacy of this vasodilator combination and to develop other safe and effective drugs that target the progressive remodeling process in heart failure.

KW - ejection fraction

KW - exercise tolerance

KW - hydralazine

KW - isosorbide dinitrate

KW - left ventricular remodeling

UR - http://www.scopus.com/inward/record.url?scp=0028225507&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028225507&partnerID=8YFLogxK

U2 - 10.1007/BF00877099

DO - 10.1007/BF00877099

M3 - Article

C2 - 8086321

AN - SCOPUS:0028225507

VL - 8

SP - 119

EP - 122

JO - Cardiovascular Drugs and Therapy

JF - Cardiovascular Drugs and Therapy

SN - 0920-3206

IS - 1

ER -